These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 18971317)
1. Drug interaction potential of 2-((3,4-dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the novel nonstatin-type cholesterol-lowering agent. Monostory K; Pascussi JM; Szabó P; Temesvári M; Köhalmy K; Acimovic J; Kocjan D; Kuzman D; Wilzewski B; Bernhardt R; Kóbori L; Rozman D Drug Metab Dispos; 2009 Feb; 37(2):375-85. PubMed ID: 18971317 [TBL] [Abstract][Full Text] [Related]
2. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Sakaeda T; Fujino H; Komoto C; Kakumoto M; Jin JS; Iwaki K; Nishiguchi K; Nakamura T; Okamura N; Okumura K Pharm Res; 2006 Mar; 23(3):506-12. PubMed ID: 16388406 [TBL] [Abstract][Full Text] [Related]
3. The effects of rosuvastatin and the CYP51A1 inhibitor LEK-935 on the proteome of primary human hepatocytes. Wörner M; Melchior K; Monostory K; Pascussi JM; Huber CG; Bernhardt R Drug Metab Dispos; 2012 Mar; 40(3):414-8. PubMed ID: 22180046 [TBL] [Abstract][Full Text] [Related]
4. Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. Park Y; Jeong YH; Tantry US; Ahn JH; Kwon TJ; Park JR; Hwang SJ; Gho EH; Bliden KP; Kwak CH; Hwang JY; Kim S; Gurbel PA Eur Heart J; 2012 Sep; 33(17):2151-62. PubMed ID: 22507978 [TBL] [Abstract][Full Text] [Related]
5. The human primary hepatocyte transcriptome reveals novel insights into atorvastatin and rosuvastatin action. Hafner M; Juvan P; Rezen T; Monostory K; Pascussi JM; Rozman D Pharmacogenet Genomics; 2011 Nov; 21(11):741-50. PubMed ID: 21869732 [TBL] [Abstract][Full Text] [Related]
6. Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and Caucasians? Comparison of the DISCOVERY-Hong Kong study with other DISCOVERY studies. Hu M; Lui SS; Ko GT; Tomlinson B Int J Cardiol; 2013 Oct; 168(3):3071-3. PubMed ID: 23642826 [No Abstract] [Full Text] [Related]
7. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Cohen LH; van Leeuwen RE; van Thiel GC; van Pelt JF; Yap SH Biopharm Drug Dispos; 2000 Dec; 21(9):353-64. PubMed ID: 11523064 [TBL] [Abstract][Full Text] [Related]
8. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia. Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760 [TBL] [Abstract][Full Text] [Related]
9. Effects of fibrates on metabolism of statins in human hepatocytes. Prueksaritanont T; Tang C; Qiu Y; Mu L; Subramanian R; Lin JH Drug Metab Dispos; 2002 Nov; 30(11):1280-7. PubMed ID: 12386136 [TBL] [Abstract][Full Text] [Related]
10. Inferring statin-induced gene regulatory relationships in primary human hepatocytes. Schröder A; Wollnik J; Wrzodek C; Dräger A; Bonin M; Burk O; Thomas M; Thasler WE; Zanger UM; Zell A Bioinformatics; 2011 Sep; 27(18):2473-7. PubMed ID: 21757465 [TBL] [Abstract][Full Text] [Related]
11. Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes. Korhonova M; Doricakova A; Dvorak Z PLoS One; 2015; 10(9):e0137720. PubMed ID: 26366873 [TBL] [Abstract][Full Text] [Related]
12. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Strandberg TE; Feely J; Sigurdsson EL; Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694 [TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Mayer C; Gruber HJ; Landl EM; Pailer S; Scharnagl H; Truschnig-Wilders M; März W Int J Clin Pharmacol Ther; 2007 Jun; 45(6):319-27. PubMed ID: 17595889 [TBL] [Abstract][Full Text] [Related]
14. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. Faucette SR; Zhang TC; Moore R; Sueyoshi T; Omiecinski CJ; LeCluyse EL; Negishi M; Wang H J Pharmacol Exp Ther; 2007 Jan; 320(1):72-80. PubMed ID: 17041008 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. Polli JW; Hussey E; Bush M; Generaux G; Smith G; Collins D; McMullen S; Turner N; Nunez DJ Xenobiotica; 2013 Jun; 43(6):498-508. PubMed ID: 23256625 [TBL] [Abstract][Full Text] [Related]
16. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. Faucette SR; Sueyoshi T; Smith CM; Negishi M; Lecluyse EL; Wang H J Pharmacol Exp Ther; 2006 Jun; 317(3):1200-9. PubMed ID: 16513849 [TBL] [Abstract][Full Text] [Related]
18. Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors. Park WK; Kennedy RM; Larsen SD; Miller S; Roth BD; Song Y; Steinbaugh BA; Sun K; Tait BD; Kowala MC; Trivedi BK; Auerbach B; Askew V; Dillon L; Hanselman JC; Lin Z; Lu GH; Robertson A; Sekerke C Bioorg Med Chem Lett; 2008 Feb; 18(3):1151-6. PubMed ID: 18155906 [TBL] [Abstract][Full Text] [Related]
19. [Pleiotropic effects of statins]. Mennickent C S; Bravo D M; Calvo M C; Avello L M Rev Med Chil; 2008 Jun; 136(6):775-82. PubMed ID: 18769836 [TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin: a review of its use in the management of dyslipidemia. Scott LJ; Curran MP; Figgitt DP Am J Cardiovasc Drugs; 2004; 4(2):117-38. PubMed ID: 15049723 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]